TPA stands for tissue plasminogen activator, a clot-dissolving protein used most commonly as an emergency treatment for ischemic stroke. Your body naturally produces small amounts of tPA to break down blood clots, but the medical version is a manufactured form given intravenously to rapidly dissolve dangerous clots blocking blood flow to the brain, heart, or lungs. It remains one of the most time-sensitive treatments in emergency medicine, with a narrow window of just a few hours to be effective.
How tPA Works in the Body
tPA is an enzyme, and its job is straightforward: it activates your body’s own clot-dissolving system. Blood clots are made of a mesh-like protein called fibrin. When tPA is present, it binds to the surface of a fibrin clot alongside an inactive protein called plasminogen. Once they’re close together, tPA cuts plasminogen at a specific point, converting it into plasmin, the enzyme that actually chews through the fibrin mesh and breaks the clot apart.
What makes this process especially fast is a built-in feedback loop. Once plasmin is produced, it modifies tPA into a more active form that is 10 times better at converting additional plasminogen into plasmin. This means clot breakdown accelerates quickly once it starts. The system is also somewhat self-targeting: tPA works most efficiently when it’s bound to fibrin, so it preferentially dissolves existing clots rather than interfering with normal clotting throughout the entire bloodstream. That said, the risk of unwanted bleeding is still the treatment’s most serious concern.
What tPA Is Used For
The most well-known use of tPA is treating ischemic stroke, which occurs when a blood clot blocks an artery supplying the brain. The FDA first approved tPA for heart attacks in 1987, then expanded approval to ischemic stroke in 1996. It is also used for massive pulmonary embolism, a life-threatening clot in the lungs.
In stroke treatment, tPA restores blood flow to brain tissue that would otherwise die from oxygen deprivation. The drug is given through an IV line, with 10% of the total dose delivered as an initial push over one minute, followed by a slower infusion of the remaining 90% over the next hour. The standard dose is based on body weight (0.9 mg per kilogram), capped at a maximum of 90 mg regardless of the patient’s size.
The Time Window That Matters
tPA for ischemic stroke must be given within three hours of symptom onset, per FDA approval. Some hospitals may extend that window to 4.5 hours in carefully selected patients, but effectiveness drops significantly with every passing minute. This is the reason behind the phrase “time is brain,” which emergency physicians use to emphasize that rapid treatment preserves more brain tissue and leads to better recovery.
The time pressure creates a practical challenge. By the time someone recognizes stroke symptoms, calls emergency services, arrives at a hospital, gets a CT scan to confirm the stroke is caused by a clot (not a bleed), and undergoes lab work, the clock may already be running out. This is why knowing stroke warning signs like sudden facial drooping, arm weakness, and speech difficulty is so important for bystanders.
Benefits and Success Rates
Patients who receive tPA within the approved time window have a meaningfully better chance of recovering with little or no disability. The landmark trial that led to FDA approval, funded by the National Institute of Neurological Disorders and Stroke, showed that patients treated with tPA were more likely to regain functional independence at 90 days compared to those who received a placebo. The benefit is largest when the drug is given as early as possible after symptoms start.
That said, tPA is not a guarantee. Some patients improve dramatically, while others see limited benefit, particularly if the clot is very large or treatment is delayed. The drug works best on smaller clots. For large vessel blockages, doctors may combine tPA with a mechanical procedure called thrombectomy, where a catheter physically removes the clot.
Risks and Side Effects
The most serious risk of tPA is bleeding in the brain, known as symptomatic intracranial hemorrhage. Across studies, this complication occurs in roughly 3.5% of patients who receive the drug. The risk is not evenly distributed. It ranges from near zero in younger patients with milder strokes to over 10% in older patients with more severe strokes. There is no significant difference in bleeding risk between men and women.
Because the drug dissolves clots throughout the body and not just the targeted one, bleeding can also occur at other sites, including the gums, urinary tract, or areas where IVs or needles were recently placed. Hospital teams monitor patients closely for at least 24 hours after administration.
Who Cannot Receive tPA
A long list of conditions disqualify someone from receiving tPA, because the bleeding risk would outweigh the benefit. The major ones include:
- Active bleeding anywhere in the body
- History of brain hemorrhage at any point in the past
- Recent head trauma or stroke within the previous three months
- Uncontrolled high blood pressure above 185/110 mmHg that cannot be brought down quickly
- Very low platelet count or use of blood-thinning medications that impair clotting
- Brain tumors, aneurysms, or abnormal blood vessel formations inside the skull
- Large areas of brain damage already visible on a CT scan, suggesting the stroke is too far advanced for the drug to help
Recent major surgery or trauma within two weeks is considered a relative contraindication, meaning doctors weigh the risks on a case-by-case basis rather than automatically ruling it out.
Newer Alternatives to Traditional tPA
The traditional form of tPA used in hospitals is called alteplase (brand name Activase). A newer version called tenecteplase has been gaining ground in clinical practice. Tenecteplase is a modified version of the same protein, engineered to last longer in the bloodstream and given as a single injection rather than a one-hour infusion. This makes it faster and simpler to administer, which is a major advantage in an emergency setting.
Alteplase remains the only FDA-approved option for ischemic stroke, but tenecteplase is increasingly used off-label. A 2025 systematic review combining data from 13 studies found that tenecteplase at a lower dose provided superior functional outcomes compared to alteplase, without increasing mortality or worsening neurological complications. Many stroke centers have already adopted it in practice, and formal guideline changes may follow as the evidence base continues to grow.